DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 50-624/S-021

Hoffmann-LaRoche, INC
Attention: Melanie Bishop
Program Director, Drug Regulatory Affairs
340 Kingsland Street
Nutley, New Jersey 07110-1199

21 NOV 2001

Dear Ms. Bishop:

Please refer to your supplemental new drug application dated October 17, 2000, received October 18, 2000, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Rocephin® (ceftriaxone injection) Galaxy Container (PL 2040). We note that this application is subject to the exemption provisions contained in section 125(d)(2) of Title I of the FDA Modernization Act of 1997.

This supplemental new drug application (NDA) 50-624/S-021 incorporates the same changes to the label that were approved in NDA 50-585/S-047. These changes are as follows:

1. The addition of the statement "Ceftriaxone crosses the blood placenta barrier" to the **CLINICAL PHARMACOLOGY** section;
2. Updated **Microbiology** and ***Susceptibility Tests*** subsections of the **CLINICAL PHARMACOLOGY** section as requested in the Agency's letter dated August 31, 1995, for NDAs 50-585/S-039 and S-043;
3. The addition of an **OVERDOSAGE** section as requested in the Agency's letter dated August 31, 1995, for NDAs 50-585/S-039 and S-043. This new section reads as follows:

   "In the case of overdosage, drug concentration would not be reduced by hemodialysis or peritoneal dialysis. There is no specific antidote. Treatment of overdosage should be symptomatic."

4. The replacement of "injection site reaction" with "warmth, tightness, or induration" under *LOCAL REACTIONS* in the **ADVERSE REACTIONS** section;
5. The addition of "biliary lithiasis, agranulocytosis, renal precipitations, and nephrolithiasis" under *MISCELLANEOUS* in the **ADVERSE REACTIONS** section;
6. Addition of a paragraph in the **DOSAGE AND ADMINISTRATION** section under *COMPATIBILITY AND STABILITY*, to describe the compatibility of ceftriaxone with metronidazole hydrochloride;
7. Addition of a paragraph in the **DOSAGE AND ADMINISTRATION** section under *COMPATIBILITY AND STABILITY*, to describe the incompatibility of ceftriaxone with vancomycin and fluconazole;
8. Addition of the following notation in the **DOSAGE AND ADMINISTRATION** section under

COMPATIBILITY AND STABILITY:

"**Note:** Parenteral drug products should be inspected visually for particulate matter before administration."

9. Updated **REFERENCES** as requested in the Agency's letter dated August 31, 1995, for NDAs 50-585/S-039 and S-043;
10. Other minor editorial revisions.

We have completed the review of this supplemental application and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the submitted final printed labeling (package insert submitted October 17, 2000). Accordingly, the supplemental application is approved effective on the date of this letter.

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call LTJG Raquel Peat, Regulatory Health Project Manager, at (301) 827-2125.

Sincerely,

Janice M. Soreth, M.D.
Acting Director
Division of Anti-Infective Drug Products
Office of Drug Evaluation IV
Center for Drug Evaluation and Research